AUA 2023 Annual Meeting

Conference Coverage

En Bloc vs Standard Resection Found to Lower Bladder Cancer Recurrence Rate

Investigators observe no significant difference between the surgical approaches in 1-year progression rates.

The EMBARK Trial: An Interview With Neal D. Shore, MD

The phase 3 EMBARK trial involved more than 200 global sites and had 8 years of follow-up.

BCG Response in Bladder Cancer Cases Linked to Tumor Microbiome

New findings suggest that Lactobacillus bacteria in the tumors of patients with non-muscle invasive bladder cancer increase uptake of bacillus Calmette-Guérin.

Novel Tibial Neurostimulator May Ease Overactive Bladder

The implant is wirelessly powered and modulated by an external wearable ankle unit.

TURP Still Most Common BPH Procedure Despite Growing Use of Other Therapies

Some studies show that use of transurethral resection of the prostate, long the gold standard for managing enlarged prostates, is in decline, but it still remains the most popular choice among surgeons amid a wide range of options.

AUA, SUO Issue New Guideline on Nonmetastatic UTUC

The new guideline aims to limit toxicity and improve cancer control and survival in patients with UTUC.

Robotic-Assisted vs Open Kidney Transplantation: The Pros and Cons

The debate was highlighted at the American Urological Association’s 2023 Annual Scientific Meeting.

Enzalutamide Ups Metastasis-Free Survival in nmHSPC

Investigators report results from the phase 3 randomized EMBARK trial.

Biochemical Recurrence Risk Differs by Prostate Cancer Zone

Finding is based on a meta-analysis of 14 high-quality studies involving 19,365 patients.

Intramuscular Testosterone Therapy Tied With Rise in Hematocrit

The risk of hematocrit elevation may depend on testosterone therapy’s route of administration, according to investigators.

UTUC Recurrence After Endoscopic Treatment ID’d as Only Mortality Predictor

Findings are based on a study of 215 patients who underwent 392 endoscopic procedures for upper tract urothelial carcinoma.

Cytoreductive Nephrectomy May Improve Quality of Life

With effective modern systemic therapies for metastatic RCC, how cytoreductive nephrectomy affects quality of life has become an increasingly relevant question, according to investigators.

Prostate Cancer Diagnoses, Treatment Patterns Changed During COVID-19 Pandemic

Men diagnosed with prostate cancer during 2020, the start of the pandemic, were more likely to have higher-stage and higher-grade disease compared with men diagnosed in 2018-2019, according to investigators.

Prostate Cancer Hits Patients With Substantial Out-of-Pocket Expenses

Investigators analyzed survey results from 495 patients with newly diagnosed localized prostate cancer.

Cytoreductive Nephrectomy Perioperative Outcomes in Metastatic RCC Improving

Patients undergoing the operation in 2015-2019 vs 2005-2009 are less likely to have major surgical complications or die within 90 days, according to a study.

Bladder Cancer Trimodal Therapy’s Effects on Long-Term Renal Function Described

Renal function declines slightly in the first year of follow-up and then remains stable through 10 years.

Cryoablation for T1a RCC Linked With Good Long-Term Outcomes

No residual malignancy was found in 98% of patients treated with percutaneous cryoablation.

Cardiovascular Disease Risks Persist for Years After Prostate Cancer Diagnosis

Cardiovascular disease is a leading cause of noncancer death in men with prostate cancer.

Prostate Cancer Recurrence Rates After Radiation Therapy ‘Fairly High’

The risk for biochemical recurrence of prostate cancer after external beam radiation therapy varies by prostate cancer risk category.

Antibiotic Prophylaxis at Catheter Removal Reduces Febrile UTI Admissions

Study findings support AUA guidelines to consider antibiotic prophylaxis at the time of catheter removal.